The ROME COPD exacerbation proposal works! Time to move forward
COPD Exacerbations Classification and the Need for Standardization
Reliable definitions and severity classification for acute medical events are essential for clinicians to establish the diagnosis, assess prognosis, and guide appropriate therapy.
These guiding principles do not exist for exacerbations of chronic obstructive pulmonary disease (COPD), where there is more than one definition, and where the severity is classified after its occurrence, by the type and site of health care provided to the patient.
ROME Proposal for COPD Exacerbations Severity Assessment
The rapidity with which the data of close to 10,000 patients have validated the potential use of the proposed ROME definition and classification of severity of COPD exacerbations, suggests that the field is ready to accept this change.
The studies here referenced agree that the proposal is applicable at the emergency room or in-hospital point-of-care, the variables included are measurable and importantly, that the obtained on-site information predicts ulterior health outcomes.
All roads seem to lead to ROME, and the challenge is to test its value in all patients with COPD thought to have an exacerbation.
Authors
Bartolome R Celli, Leonardo M Fabbri, Gerard J Criner, Alberto Papi, Antoni Torres, Alvar Agusti
Read more details at
Fecha de publicación
Published 14 October 2025
Categorías asociadas al artículo
Noticias relacionadas
Video del evento: Transformando la EPOC, claves para un manejo proactivo
Conferencia sobre el manejo proactivo de la EPOC centrada en el infradiagnóstico, el control clínico y el seguimiento estructurado del paciente.
ECLIPSE: un estudio de tres años que cambió nuestra forma de entender la EPOC
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
Vídeo de la Presentación de las Novedades GOLD 2026
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
A Bispecific Monoclonal Antibody Targeting Psl and PcrV for Chronic Pseudomonas Aeruginosa Infection in Patients With Bronchiectasis: Results From a Randomized, Double-Blind Placebo-Controlled Trial (GREAT-2)
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Imagen creada con ChatGPT